|
시장보고서
상품코드
2103552
나노바이오테크놀러지 시장 : 세계 예측(2026-2032년)Nanobiotechnology Market - Global Forecast 2026-2032 |
||||||
360iResearch
나노바이오테크놀러지 시장은 2032년까지 연평균 복합 성장률(CAGR) 13.90%로 성장해 2,005억 5,000만 달러 규모로 확대될 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도(2025년) | 806억 1,000만 달러 |
| 추정 연도(2026년) | 911억 7,000만 달러 |
| 예측 연도(2032년) | 2,005억 5,000만 달러 |
| CAGR(%) | 13.90% |
나노바이오테크놀러지는 나노기술, 분자생물학, 재료과학, 생체의료공학의 교차점에 위치하며, 나노 규모에서 생물 시스템을 조작할 수 있게 함으로써 진단, 치료, 재생의료, 바이오센싱, 농업, 환경 모니터링의 향상에 기여하고 있습니다. 이 부문은 나노 규모의 약물 전달 시스템, 지질 및 고분자 나노입자, 나노바이오센서, 랩온어칩 플랫폼, 양자점, 나노자임, DNA 나노구조, 나노입자를 이용한 영상제 등을 통해 발전하고 있습니다. 의료 시스템이 질환의 조기 발견, 보다 표적화된 치료, 저용량 개입, 정밀 의학을 위한 확장 가능한 도구를 추구함에 따라 그 중요성은 더욱 커지고 있습니다.
입증된 과학적 진보는 나노바이오테크놀러지이 이미 실제 생의학적 실무에 정착했음을 보여줍니다. 지질 나노입자를 이용한 전달 기술은 핵산 기반 백신 및 치료를 통해 그 유효성이 입증되었으며, 일부 나노입자 기반 의약품은 종양학, 감염증, 염증성 질환, 희귀질환에 대한 적용에 대해 규제 당국의 승인을 받았습니다. 동시에 규제 당국은 특성 평가, 무균성 확보, 생체 적합성, 생체 내 분포, 면역원성, 장기적 안전성에 대한 요건을 강화하고 있습니다. 그 결과, 나노바이오테크놀러지 분야는 중개 연구의 엄격성, 재현 가능한 제조, 품질 설계(QbD) 원칙, 생명과학, 계산 생물학, 마이크로플루이딕스 공학, 첨단 재료 과학에 걸친 학제 간 협력을 통해 점점 더 명확히 정의되고 있습니다.
나노바이오테크놀러지의 전망을 재구성하는 혁신적인 변화
나노바이오테크놀러지 분야는 생물학적 제제, 첨단 소재, 디지털 설계, 현장 진단(POC)의 융합에 힘입어 혁신적인 변화를 겪고 있습니다. 가장 중요한 변화 중 하나는 탐색적 나노 소재에서 임상적 및 산업적으로 검증된 플랫폼으로의 전환입니다. 연구자와 개발자들은 확장 가능한 합성, 배치 간 균일성, 표면 기능화 제어, 전자 현미경, 동적 광산란법, 나노입자 추적 분석, 크로마토그래피, 질량 분석, 고분해능 분광법 등 규제 기준을 충족하는 분석 기법을 그 어느 때보다 중요하게 여기고 있습니다.
나노바이오테크놀러지에 대한 인공지능의 누적 영향
인공지능은 물질 발견을 가속화하고, 나노입자 설계를 최적화하며, 생물학적 표적화를 개선하고, 데이터 분석을 강화함으로써 나노바이오테크놀러지 전반에 누적 영향을 미치고 있습니다. 머신러닝 모델은 입자 직경, 전하, 형태, 표면 화학, 유효 성분의 특성, 방출 동역학, 독성, 생물학적 흡수 간의 복잡한 관계를 분석할 수 있습니다. 이를 통해 연구자는 실험 조건을 좁히고, 시행착오의 주기를 단축하며, 안전성과 유효성 프로파일이 더 우수한 제제를 식별할 수 있게 됩니다.
아시아태평양, 유럽, 북미, 라틴아메리카, 아프리카, 중동의 주요 지역별 인사이트
아시아태평양은 생명공학, 나노과학, 반도체를 활용한 계측 기기, 바이오 제조에 대한 강력한 공공 투자의 뒷받침을 받아 나노바이오테크놀러지 활동의 주요 중심지로 자리 잡고 있습니다. 중국, 일본, 인도, 한국, 호주, 아세안(ASEAN)은 산학 협력 연구 네트워크 및 임상 연구 인프라 확충을 통해 나노 스케일 진단 기술, 나노 의료, 생체 재료, 농업용 나노기술 개발을 추진하고 있습니다. 북미는 성숙한 생물의학 연구 생태계, 나노의약품에 관한 규제 경험, 첨단 특성 평가 시설, 그리고 RNA 전달, 종양학 나노 치료, 바이오센서, 맞춤형 의료 분야의 활발한 활동을 바탕으로 여전히 큰 영향력을 유지하고 있습니다.
NATO, G7, BRICS, 유럽연합(EU), ASEAN, GCC에 관한 주요 그룹 분석
NATO 회원국들은 바이오 감시, 신속 진단, 상처 치료, 방호 소재, 환경 모니터링, 공중보건의 회복탄력성 및 대비 태세를 강화할 수 있는 생체 반응 시스템과 같은 군민 양용 연구 분야를 통해 나노바이오테크놀러지에 기여하고 있습니다. G7 국가들은 첨단 연구 기관, 정교한 규제 시스템, 지적 재산의 집중도, 탄탄한 임상 인프라, 복잡한 생물학적 제제, 의료기기, 나노 의약품 평가에 활용되는 확립된 프로세스를 바탕으로, 하이엔드 나노바이오테크놀러지 개발에서 여전히 중심적인 역할을 수행하고 있습니다. BRICS 국가들은 대규모 환자층, 확대되는 생명공학 역량, 제조의 고도화, 견고한 과학 연구 기반을 모두 갖추고 있어, 의약품, 백신, 진단, 농업, 산업용 바이오프로세싱 분야의 중개형 나노바이오테크놀러지 부문에서 중요한 역할을 수행하고 있습니다.
주요 나노바이오테크놀러지 혁신 허브별 국가별 인사이트
중국은 대규모 과학 인프라와 제조 역량을 바탕으로 나노의료, 나노소재, 바이오센서, 생체의공학 분야에서 성과를 급성장하고 있습니다. 미국은 광범위한 생의학 연구에 대한 자금 지원, 첨단 임상 검사 인프라, 복잡한 생물학적 제제 및 나노의약품에 대한 규제 경험, 그리고 RNA 전달, 종양학, 영상, 바이오센서 부문에서의 활발한 활동을 통해 나노바이오테크놀러지의 실용화를 주도하고 있습니다. 일본은 정밀 공학, 재생의학, 영상, 생체재료, 고품질 계측 기기 분야에서 강점을 발휘하고 있습니다. 한편, 인도는 저렴한 의료, 백신, 진단, 농업, 수질 정화에 활용되는 나노바이오테크놀러지을 추진하고 있으며, 이는 확장성이 높고 비용 대비 효과가 뛰어난 혁신을 국가적 우선 과제로 삼고 있음을 반영합니다.
나노바이오테크놀러지 산업의 리더를 위한 실천적 제안
산업 리더는 나노바이오테크놀러지 개발의 초기 단계부터 실용화를 위한 준비를 우선시해야 합니다. 여기에는 명확한 임상적 또는 산업적 이용 사례를 염두에 둔 나노 물질 설계, 견고한 물리화학적 특성 평가 프로토콜 수립, 안정성 및 재현성 문서화, 안전성, 품질, 성능에 관한 규제 당국의 기대에 부합하는 개발 계획 수립이 포함됩니다. '품질 설계(Quality by Design)' 프레임워크를 구축함으로써, 특히 나노 입자 기반 치료, 진단 플랫폼, 생리활성 코팅, 바이오센싱 장치 분야에서 개발 후기 단계의 위험을 줄일 수 있습니다.
신뢰할 수 있는 나노바이오테크놀러지 정보 수집을 위한 조사 기법
엄격한 나노바이오테크놀러지 연구 방법론에는 2차 조사, 전문가에 의한 1차 검증, 규제 당국의 심사, 기술적 평가를 결합해야 합니다. 2차 조사에는 동료 심사를 거친 학술지, 특허 데이터베이스, 임상시험 등록부, 규제 지침 문서, 공중보건 관련 간행물, 정부 연구 프로그램, 공인된 과학·규제 기관의 기준이 포함됩니다. 1차 조사에서는 과학자, 임상의, 규제 전문가, 제조 전문가, 독성학자, 품질 관리 책임자, 조달 이해관계자와의 구조화된 인터뷰를 통해 기술 도입 패턴, 충족되지 않은 요구 사항, 상용화의 장벽을 검증해야 합니다.
결론 : 나노바이오테크놀러지는 확장 가능하고 책임감 있는 혁신으로 나아가고 있습니다.
나노바이오테크놀러지는 정밀의료, 첨단 진단, 지속 가능한 농업, 환경 모니터링, 차세대 생체 재료 분야의 전략적 축으로 자리 잡고 있습니다. 이러한 발전은 나노 입자 전달, 나노 스케일 센싱, 생체 기능성 소재, 마이크로플루이딕스 공학, AI를 활용한 설계 분야에서 입증된 진전에 의해 뒷받침되고 있습니다. 이 분야의 향후 방향성은 단순한 신규성보다는 재현성, 안전성, 규제의 명확성, 제조 가능성, 입증된 생물학적 가치에 크게 좌우될 것으로 보입니다.
자주 묻는 질문
목차
제1장 서문
제2장 조사 방법
제3장 주요 요약
제4장 시장 개요
제5장 시장 인사이트
제6장 AI의 누적 영향(2026년)
제7장 나노바이오테크놀러지 시장 : 재료 유형별
제8장 나노바이오테크놀러지 시장 : 기술별
제9장 나노바이오테크놀러지 시장 : 최종 사용자 산업별
제10장 나노바이오테크놀러지 시장 : 용도별
제11장 나노바이오테크놀러지 시장 : 지역별
제12장 나노바이오테크놀러지 시장 : 그룹별
제13장 나노바이오테크놀러지 시장 : 국가별
제14장 경쟁 구도
제15장 기업 개요
KTH 26.08.12The Nanobiotechnology Market is projected to grow by USD 200.55 billion at a CAGR of 13.90% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 80.61 billion |
| Estimated Year [2026] | USD 91.17 billion |
| Forecast Year [2032] | USD 200.55 billion |
| CAGR (%) | 13.90% |
Nanobiotechnology sits at the intersection of nanotechnology, molecular biology, materials science, and biomedical engineering, enabling manipulation of biological systems at the nanoscale to improve diagnostics, therapeutics, regenerative medicine, biosensing, agriculture, and environmental monitoring. The field is advancing through nanoscale drug delivery systems, lipid and polymer nanoparticles, nanobiosensors, lab-on-a-chip platforms, quantum dots, nanozymes, DNA nanostructures, and nanoparticle-enabled imaging agents. Its relevance has increased as healthcare systems seek earlier disease detection, more targeted therapies, lower-dose interventions, and scalable tools for precision medicine.
Verified scientific progress shows that nanobiotechnology is already embedded in real-world biomedical practice. Lipid nanoparticle delivery has been validated through nucleic-acid-based vaccines and therapeutics, and several nanoparticle-based medicines have received regulatory authorization for oncology, infectious disease, inflammatory conditions, and rare disease applications. At the same time, regulatory agencies have strengthened expectations for characterization, sterility assurance, biocompatibility, biodistribution, immunogenicity, and long-term safety. As a result, the nanobiotechnology landscape is increasingly defined by translational rigor, reproducible manufacturing, quality-by-design principles, and multidisciplinary collaboration across life sciences, computational biology, microfluidics, and advanced materials.
Transformative Shifts Reshaping the Nanobiotechnology Landscape
The nanobiotechnology landscape is undergoing transformative shifts driven by convergence across biologics, advanced materials, digital design, and point-of-care diagnostics. One of the most important changes is the movement from exploratory nanomaterials toward clinically and industrially validated platforms. Researchers and developers are placing greater emphasis on scalable synthesis, batch-to-batch consistency, surface functionalization control, and regulatory-grade analytical methods such as electron microscopy, dynamic light scattering, nanoparticle tracking analysis, chromatography, mass spectrometry, and high-resolution spectroscopy.
Another major shift is the expansion of nanobiotechnology beyond drug delivery into integrated diagnostic and therapeutic systems. Nanobiosensors are being developed for rapid detection of biomarkers, pathogens, toxins, and environmental contaminants, while microfluidic and lab-on-a-chip systems are enabling low-volume sample processing and decentralized testing. In therapeutics, stimulus-responsive nanoparticles, targeted delivery ligands, RNA delivery vehicles, extracellular vesicle-inspired systems, and bioinspired nanostructures are supporting more selective interactions with diseased tissues. Sustainability is also shaping the field, with rising interest in green synthesis, biodegradable nanomaterials, reduced solvent use, and safer-by-design nanomaterial development. Together, these shifts are turning nanobiotechnology from a specialized research domain into a foundational enabling technology for next-generation healthcare, food safety, agriculture, and environmental resilience.
Cumulative Impact of Artificial Intelligence on Nanobiotechnology
Artificial intelligence is creating a cumulative impact across nanobiotechnology by accelerating material discovery, optimizing nanoparticle design, improving biological targeting, and strengthening data interpretation. Machine learning models can analyze complex relationships between particle size, charge, morphology, surface chemistry, payload properties, release kinetics, toxicity, and biological uptake. This helps researchers narrow experimental conditions, reduce trial-and-error cycles, and identify formulations with more favorable safety and efficacy profiles.
AI is also enhancing nanomedicine development through predictive toxicology, omics integration, image analysis, and simulation of nano-bio interactions. Deep learning tools support automated interpretation of microscopy and imaging datasets, while computational models help predict protein corona formation, cellular internalization, biodistribution, and immune response. In diagnostics, AI-enabled nanobiosensing can improve signal processing, pattern recognition, and multiplex biomarker interpretation, supporting earlier and more accurate detection workflows. However, the value of AI depends on high-quality datasets, standardized metadata, transparent validation, and regulatory acceptance. Industry leaders are therefore prioritizing explainable models, reproducible experimental design, and secure data governance to ensure that AI strengthens rather than complicates nanobiotechnology translation.
Key Regional Insights Across Asia-Pacific, Europe, North America, Latin America, Africa, and Middle East
Asia-Pacific is a major center of nanobiotechnology activity, supported by strong public investment in biotechnology, nanoscience, semiconductor-enabled instrumentation, and biomanufacturing. China, Japan, India, South Korea, Australia, and ASEAN economies are advancing nanoscale diagnostics, nanomedicine, biomaterials, and agricultural nanotechnology through university-industry research networks and expanding clinical research infrastructure. North America remains highly influential due to mature biomedical research ecosystems, regulatory experience with nanomedicines, advanced characterization facilities, and strong activity in RNA delivery, oncology nanotherapeutics, biosensors, and personalized medicine.
Europe is characterized by strong regulatory oversight, materials safety programs, cross-border research collaboration, and emphasis on responsible innovation, sustainability, and nanomaterial risk assessment. European institutions have advanced nanosafety, chemical assessment, medical technology regulation, and public research collaboration, supporting controlled translation of nanobiotechnology into healthcare and industrial use. Latin America is developing capabilities through academic research, public health applications, agricultural biotechnology, water-quality monitoring, and infectious disease diagnostics, with Brazil and Mexico playing visible roles in regional scientific output. The Middle East is increasingly investing in biotechnology infrastructure, precision medicine, desalination-related nanotechnology, and academic research clusters, while Africa is gaining relevance through applications in low-cost diagnostics, infectious disease surveillance, food security, and environmental monitoring. Across all regions, adoption is shaped by scientific capacity, regulatory readiness, healthcare priorities, manufacturing infrastructure, and access to advanced analytical tools.
Key Group Insights for NATO, G7, BRICS, European Union, ASEAN, and GCC
NATO-aligned economies contribute to nanobiotechnology through dual-use research areas such as biosurveillance, rapid diagnostics, wound care, protective materials, environmental monitoring, and bioresponsive systems that can strengthen public health resilience and preparedness. G7 countries remain central to high-end nanobiotechnology development due to advanced research institutions, sophisticated regulatory systems, intellectual property intensity, deep clinical infrastructure, and established pathways for complex biologics, medical devices, and nanomedicine evaluation. BRICS economies combine large patient populations, expanding biotechnology capabilities, manufacturing depth, and strong scientific research bases, making them important for translational nanobiotechnology in pharmaceuticals, vaccines, diagnostics, agriculture, and industrial bioprocessing.
The European Union provides one of the most structured environments for nanobiotechnology, with coordinated research funding, strong regulatory science, chemical safety frameworks, medical device requirements, and responsible innovation policies influencing the development of nanomaterials and nanomedicine. ASEAN is strengthening its role through healthcare modernization, university-led nanoscience programs, biomedical engineering, agricultural innovation, and point-of-care diagnostic development suited to diverse public health environments. GCC countries are investing in life sciences, precision medicine, advanced healthcare infrastructure, and research parks, creating opportunities for nanobiotechnology applications in diagnostics, drug delivery, environmental sensing, and water treatment. These groups reflect different policy priorities, but all are increasing attention on safety, reproducibility, supply-chain resilience, and cross-disciplinary research capacity.
Key Country Insights Across Major Nanobiotechnology Innovation Hubs
China has rapidly expanded output in nanomedicine, nanomaterials, biosensors, and biomedical engineering, supported by large-scale scientific infrastructure and manufacturing capacity. The United States leads in nanobiotechnology translation through extensive biomedical research funding, advanced clinical trial infrastructure, regulatory experience with complex biologics and nanomedicines, and strong activity in RNA delivery, oncology, imaging, and biosensors. Japan brings strengths in precision engineering, regenerative medicine, imaging, biomaterials, and high-quality instrumentation, while India is advancing nanobiotechnology for affordable healthcare, vaccines, diagnostics, agriculture, and water purification, reflecting national priorities in scalable and cost-efficient innovation.
Germany is especially recognized for engineering, materials characterization, and applied biomedical technologies, while the United Kingdom contributes significantly to nanomedicine, biosensing, life sciences research, and translational health innovation. Australia is active in biomedical nanotechnology, drug delivery, vaccines, and translational research, and France adds strong capabilities in nanomedicine, biosensing, materials science, and life sciences research. South Korea combines biotechnology, electronics, advanced materials, and digital health capabilities to support nanoscale diagnostics, therapeutics, and bio-integrated devices. Italy and Spain contribute through biomaterials, diagnostics, medical technology development, and translational biomedical science, supported by European safety and quality standards.
Canada contributes through nanomedicine, biomaterials, vaccine research, and translational health science, while Russia has established scientific capacity in nanomaterials, biotechnology, and biomedical research, with activity influenced by domestic research priorities and international collaboration constraints. Brazil is prominent in Latin America for nanotechnology research applied to medicine, agriculture, infectious disease, and environmental monitoring, and Mexico is building relevance in biomedical engineering, public health diagnostics, nanomaterials research, and academic-industrial collaboration. Together, these country ecosystems show that nanobiotechnology innovation is increasingly distributed across advanced research economies and emerging scientific hubs, with progress shaped by funding continuity, regulatory clarity, manufacturing readiness, and access to advanced analytical infrastructure.
Actionable Recommendations for Nanobiotechnology Industry Leaders
Industry leaders should prioritize translational readiness from the earliest stages of nanobiotechnology development. This includes designing nanomaterials with clear clinical or industrial use cases, establishing robust physicochemical characterization protocols, documenting stability and reproducibility, and aligning development plans with regulatory expectations for safety, quality, and performance. Building quality-by-design frameworks can reduce late-stage development risk, especially for nanoparticle-based therapeutics, diagnostic platforms, bioactive coatings, and biosensing devices.
Leaders should also invest in AI-enabled formulation design, standardized data infrastructure, and interoperable laboratory workflows to accelerate discovery while improving reproducibility. Strategic partnerships with hospitals, academic laboratories, contract research organizations, standards bodies, and regulatory experts can improve access to biological validation, advanced imaging, toxicology testing, and clinical evidence generation. Organizations should strengthen supply-chain resilience for critical lipids, polymers, reagents, microfluidic components, reference materials, and analytical instruments. Finally, responsible innovation should remain central: safer-by-design nanomaterials, transparent risk communication, environmental lifecycle assessment, and ethical data governance will be essential for stakeholder trust and long-term adoption.
Research Methodology for Reliable Nanobiotechnology Intelligence
A rigorous nanobiotechnology research methodology should combine secondary research, primary expert validation, regulatory review, and technical assessment. Secondary research involves peer-reviewed journals, patent databases, clinical trial registries, regulatory guidance documents, public health publications, government research programs, and standards from recognized scientific and regulatory bodies. Primary research should include structured interviews with scientists, clinicians, regulatory specialists, manufacturing experts, toxicologists, quality leaders, and procurement stakeholders to validate technology adoption patterns, unmet needs, and translational barriers.
Technical analysis should examine nanomaterial type, particle characteristics, biological payload, route of administration, diagnostic format, manufacturing method, sterilization approach, analytical validation, biocompatibility, biodistribution, immunogenicity, stability, and environmental considerations. Cross-verification is essential because nanobiotechnology evidence often varies by formulation, disease area, biological model, and measurement technique. A reliable methodology must avoid unsupported assumptions and should separate laboratory feasibility from clinically validated performance. It should also incorporate regional policy context, regulatory classification, reimbursement considerations, intellectual property activity, and standards related to nanomaterial safety and medical product quality.
Conclusion: Nanobiotechnology Advances Toward Scalable and Responsible Innovation
Nanobiotechnology is becoming a strategic pillar of precision healthcare, advanced diagnostics, sustainable agriculture, environmental monitoring, and next-generation biomaterials. Its progress is supported by validated advances in nanoparticle delivery, nanoscale sensing, biofunctional materials, microfluidics, and AI-enabled design. The field's future direction will depend less on novelty alone and more on reproducibility, safety, regulatory clarity, manufacturability, and demonstrated biological value.
Regional ecosystems are advancing at different speeds, but global momentum is clear across Asia-Pacific, Europe, North America, Latin America, Africa, and the Middle East. Governments, research institutions, and industry participants are increasingly aligning around targeted therapy, rapid diagnostics, resilient supply chains, nanosafety, and responsible nanomaterial development. Organizations that combine strong scientific validation with scalable manufacturing, data-driven design, and proactive risk management will be best positioned to convert nanobiotechnology innovation into practical, trusted, and widely adopted solutions.
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. New Revenue Opportunities
- 3.5. Next-Generation Business Models
- 3.6. Industry Roadmap
4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
- 4.4. Porter's Five Forces Analysis
- 4.5. PESTLE Analysis
- 4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
- 4.7. Go-to-Market Strategy
5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Nanobiotechnology Market, by Material Type
- 7.1. Introduction
- 7.2. Carbon-Based
- 7.2.1. Carbon Nanotubes
- 7.2.2. Fullerenes
- 7.2.3. Graphene
- 7.3. Ceramic-Based
- 7.3.1. Alumina Nanoparticles
- 7.3.2. Silica Nanoparticles
- 7.3.3. Zirconia Nanoparticles
- 7.4. Lipid-Based
- 7.4.1. Liposomes
- 7.4.2. Solid Lipid Nanoparticles
- 7.5. Metal-Based
- 7.5.1. Gold Nanoparticles
- 7.5.2. Iron Oxide Nanoparticles
- 7.5.3. Silver Nanoparticles
- 7.6. Polymer-Based
- 7.6.1. Biodegradable Polymers
- 7.6.2. Natural Polymers
- 7.6.3. Synthetic Polymers
8. Nanobiotechnology Market, by Technology
- 8.1. Introduction
- 8.2. Nanoemulsion Technology
- 8.2.1. Oil-In-Water
- 8.2.2. Water-In-Oil
- 8.3. Nanofluidics
- 8.3.1. Channels
- 8.3.2. Funnels
- 8.4. Nanolithography
- 8.4.1. Electron Beam Lithography
- 8.4.2. Nanoimprint Lithography
- 8.5. Nanoparticle Technology
- 8.5.1. Lipid Nanoparticles
- 8.5.2. Metal Nanoparticles
- 8.5.3. Polymer Nanoparticles
- 8.5.4. Quantum Dots
- 8.6. Nanorobotics
- 8.6.1. Drug Delivery Nanorobots
- 8.6.2. Surgical Nanorobots
9. Nanobiotechnology Market, by End User Industry
- 9.1. Introduction
- 9.2. Pharmaceutical Companies
- 9.3. Biotechnology Companies
- 9.4. Hospitals And Clinics
- 9.5. Research And Academic Institutes
10. Nanobiotechnology Market, by Application
- 10.1. Introduction
- 10.2. Diagnostics
- 10.2.1. In Vitro Diagnostics
- 10.2.2. In Vivo Imaging
- 10.2.3. Point Of Care Testing
- 10.3. Drug Delivery
- 10.3.1. Oral Delivery
- 10.3.2. Parenteral Delivery
- 10.3.3. Pulmonary Delivery
- 10.3.4. Topical Delivery
- 10.4. Imaging
- 10.4.1. CT Contrast
- 10.4.2. MRI Contrast
- 10.4.3. Optical Imaging
- 10.4.4. Ultrasound Imaging
- 10.5. Therapeutics
- 10.5.1. Antibacterial Therapy
- 10.5.2. Cancer Therapy
- 10.5.3. Gene Therapy
- 10.6. Tissue Engineering
- 10.6.1. Bone Tissue
- 10.6.2. Cardiovascular Tissue
- 10.6.3. Neural Tissue
- 10.6.4. Skin Tissue
11. Nanobiotechnology Market, by Region
- 11.1. Asia-Pacific
- 11.2. Europe
- 11.3. North America
- 11.4. Latin America
- 11.5. Africa
- 11.6. Middle East
12. Nanobiotechnology Market, by Group
- 12.1. NATO
- 12.2. G7
- 12.3. BRICS
- 12.4. European Union
- 12.5. ASEAN
- 12.6. GCC
13. Nanobiotechnology Market, by Country
- 13.1. China
- 13.2. United States
- 13.3. Japan
- 13.4. India
- 13.5. Germany
- 13.6. United Kingdom
- 13.7. Australia
- 13.8. France
- 13.9. South Korea
- 13.10. Italy
- 13.11. Canada
- 13.12. Russia
- 13.13. Brazil
- 13.14. Mexico
- 13.15. Spain
14. Competitive Landscape
- 14.1. Market Share Analysis, 2025
- 14.2. FPNV Positioning Matrix, 2025
- 14.3. Market Concentration Analysis, 2025
- 14.3.1. Concentration Ratio (CR)
- 14.3.2. Herfindahl Hirschman Index (HHI)
- 14.4. Recent Developments & Impact Analysis, 2025
- 14.5. Product Portfolio Analysis, 2025
- 14.6. Benchmarking Analysis, 2025
15. Company Profiles
- 15.1. 3M Company
- 15.2. Agilent Technologies, Inc.
- 15.3. Analog Devices, Inc.
- 15.4. ANSELL LTD.
- 15.5. Arkema S.A.
- 15.6. Bruker Corporation
- 15.7. DuPont de Nemours, Inc.
- 15.8. Eurofins Scientific SE
- 15.9. Evonik Industries AG
- 15.10. Honeywell International Inc.
- 15.11. Merck KGaA
- 15.12. Nanoscience Instruments, Inc.
- 15.13. Nanospan Inc.
- 15.14. Sioen Industries NV
- 15.15. Texas Instruments Incorporated
- 15.16. Thermo Fisher Scientific Inc.
